The Impact of Chemo-Sensitivity on Surgical Resection in MYCN-Amplified Neuroblastoma

被引：0
|
作者：
Chui, C. H. [1 ]
机构：
[1] Surg Ctr Children Pte Ltd, Surg Oncol, Singapore, Singapore
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IPSO23 SIO
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [31] GENETIC VARIANTS IN KIF15 ARE ASSOCIATED WITH MYCN-AMPLIFIED NEUROBLASTOMA
    Applebaum, M. A.
    Hungate, E.
    Skol, A.
    Vaksman, Z.
    Diamond, M.
    McDaniel, L.
    Volchenboum, S.
    Stranger, B.
    Diskin, S.
    Maris, J.
    Onel, K.
    Cohn, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S21
  • [32] Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
    Valind, Anders
    Verhoeven, Bronte Manouk
    Enoksson, Jens
    Karlsson, Jenny
    Christensson, Gustav
    Manas, Adriana
    Aaltonen, Kristina
    Jansson, Caroline
    Bexell, Daniel
    Baryawno, Ninib
    Gisselsson, David
    Hagerling, Catharina
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [33] The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma
    Wang, Donghai
    Yin, Zhinang
    Wang, Honghong
    Wang, Liyuan
    Li, Tianyu
    Xiao, Ruijing
    Xie, Ting
    Han, Ruyi
    Dong, Rui
    Liu, Hudan
    Liang, Kaiwei
    Qing, Guoliang
    SCIENCE ADVANCES, 2023, 9 (13)
  • [34] Favorable histology, MYCN-amplified 4S neonatal neuroblastoma
    Chan, Edward L.
    Harris, Richard E.
    Emery, Kathleen H.
    Gelfand, Michael J.
    Collins, Margaret H.
    Gruppo, Ralph A.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (04) : 479 - 482
  • [35] GMDS is a key driver of MYCN-amplified neuroblastoma core fucosylation and tumorigenesis
    Zhu, Beibei
    Pitts, Michelle
    Buoncristiani, Michael
    Bryant, Lindsay
    Lopez-Nunez, Oscar
    Gurria, Juan
    Shedlock, Cameron
    Ribas, Roberto
    Keohane, Shannon
    Liu, Jinpeng
    Wang, Chi
    Gentry, Matt
    Shelman, Nathan
    Allison, Derek
    Evers, B. Mark
    Sun, Ramon
    Rellinger, Eric J.
    CANCER RESEARCH, 2024, 84 (06)
  • [36] The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma
    Bogen, Dominik
    Brunner, Clemens
    Walder, Diana
    Ziegler, Andrea
    Abbasi, Reza
    Ladenstein, Ruth L.
    Noguera, Rosa
    Martinsson, Tommy
    Amann, Gabriele
    Schilling, Freimut H.
    Ussowicz, Marek
    Benesch, Martin
    Ambros, Peter F.
    Ambros, Inge M.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 153 - 163
  • [37] CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma
    Yoda, Hiroyuki
    Weiss, William A.
    NEURO-ONCOLOGY, 2022, 24 (06) : 886 - 887
  • [38] Transcriptional Repression of SKP2 Is Impaired in MYCN-Amplified Neuroblastoma
    Muth, Daniel
    Ghazaryan, Seda
    Eckerle, Isabella
    Beckett, Emily
    Poehler, Christina
    Batzler, Julia
    Beisel, Claudia
    Gogolin, Sina
    Fischer, Matthias
    Henrich, Kai-Oliver
    Ehemann, Volker
    Gillespie, Paul
    Schwab, Manfred
    Westermann, Frank
    CANCER RESEARCH, 2010, 70 (09) : 3791 - 3802
  • [39] Imipridones show pre-clinical efficacy in MYCN-amplified and MYCN non-amplified neuroblastoma cell lines
    Triboulet, Robinson
    Sadykov, Khikmet
    Johnson, Jessica L.
    Snyder, Andrew R.
    Knutson, Sarah K.
    Kumar, Pavan
    Mayo, Christopher B.
    Hawley, Dillon
    Madanjian, Andrew
    Stein, Ross L.
    Wilson, David M.
    Harvey, Darren M.
    Ghosh, Shomir
    Campbell, Robert M.
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes
    Sarkar, AK
    Nuchtern, JG
    CANCER RESEARCH, 2000, 60 (07) : 1908 - 1913
12345